LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Lista de Ações・CytoSorbents Corp

CytoSorbents Corp

Fechado

SetorSaúde

0.44 2.33

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

0.43

Máximo

0.45

Indicadores-chave
By Trading Economics
Rendimento	368K -5.1M
Vendas	-370K 8.9M
EPS	-0.08
Margem de lucro	-57.863
Funcionários	129
EBITDA	648K -3M

Recomendações
By TipRanks
Recomendações	Neutro
Previsão para 12 meses	+63.04% upside

Dividendos
By Dow Jones
Próximos Ganhos	6 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-9.5M 30M
Abertura anterior	-1.89
Fecho anterior	0.44

Sentimento de Notícias

By Acuity

46%

54%

135 / 345 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

0.705 / 0.771 Suporte e Resistência

CytoSorbents Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

21 de mai. de 2026, 22:48 UTC

Aquisições, Fusões, Aquisições de Empresas

Conduent to Sell Public Transit Business to Modaxo for $164 Million

21 de mai. de 2026, 16:49 UTC

Ganhos

Walmart's Fuel Business Benefits from Rising U.S. Gas Prices, Though Volume Per Transaction Falls -- OPIS

21 de mai. de 2026, 16:26 UTC

Grandes Movimentos do Mercado

Spotify Technology Shares Up Amid New AI Tool For Remixing Songs

21 de mai. de 2026, 23:51 UTC

Conversa de Mercado

Nikkei Might Rise on Continued Hopes for Possible U.S.-Iran Deal -- Market Talk

21 de mai. de 2026, 23:37 UTC

Ganhos

Lenovo Group 4Q Oper Profit $886.0M Vs. $331.0M >0992.HK

21 de mai. de 2026, 23:37 UTC

Ganhos

Lenovo Group 4Q Rev $21.60B Vs. $16.98B >0992.HK

21 de mai. de 2026, 23:37 UTC

Ganhos

Lenovo Group 4Q Net $521.0M Vs. Net $90.0M >0992.HK

21 de mai. de 2026, 23:34 UTC

Conversa de Mercado

Gold Edges Lower Amid Mixed Sentiment -- Market Talk

21 de mai. de 2026, 23:30 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

21 de mai. de 2026, 23:30 UTC

Conversa de Mercado

Napier Port Loses Bull Despite Robust 1H Result -- Market Talk

21 de mai. de 2026, 22:33 UTC

Aquisições, Fusões, Aquisições de Empresas

Conduent to Sell Public Transit Business to Modaxo for $164M

21 de mai. de 2026, 21:53 UTC

Ganhos

Marvell Stock Notches Its 15th Record Closing High This Year -- Barrons.com

21 de mai. de 2026, 21:02 UTC

Ganhos

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, Nebius, Bloom Energy, Applied Digital, Intuit, D-Wave, Spotify, and More -- Barrons.com

21 de mai. de 2026, 20:55 UTC

Ganhos

Walmart Sales Rise as It Navigates Higher Fuel Prices -- 2nd Update

21 de mai. de 2026, 20:30 UTC

Ações em Alta

Stocks to Watch Recap: Nvidia, Spotify, Stellantis, Intuit -- WSJ

21 de mai. de 2026, 20:20 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

21 de mai. de 2026, 20:20 UTC

Conversa de Mercado

Mexico's Revised 1Q GDP Seen Confirming Contraction -- Market Talk

21 de mai. de 2026, 20:20 UTC

Ganhos

Webull 1Q Adj EPS 3c >BULL

21 de mai. de 2026, 20:20 UTC

Ganhos

Webull 1Q Rev $159.9M >BULL

21 de mai. de 2026, 20:18 UTC

Conversa de Mercado

Mexico's Inflation Seen Easing in Early May -- Market Talk

21 de mai. de 2026, 20:18 UTC

Ganhos

Webull 1Q Loss/Shr 4c

21 de mai. de 2026, 19:43 UTC

Conversa de Mercado

Oil Futures Lose Ground on Hopes for U.S.-Iran Deal -- Market Talk

21 de mai. de 2026, 19:33 UTC

Conversa de Mercado

U.S. Natural Gas Futures Edge Up in Steady Trading -- Market Talk

21 de mai. de 2026, 18:58 UTC

Ganhos

Nvidia Is Now the Megacap Cash Machine, and Big Tech Is Footing the Bill -- Barrons.com

21 de mai. de 2026, 18:15 UTC

Conversa de Mercado

Gold Higher For Second Consecutive Day -- Market Talk

21 de mai. de 2026, 17:40 UTC

Conversa de Mercado

Prolonged War Putting Energy Normalcy Further Away -- Market Talk

21 de mai. de 2026, 17:04 UTC

Conversa de Mercado

SpaceX Revealed as Top 10 Bitcoin Holder -- Market Talk

21 de mai. de 2026, 17:01 UTC

Ganhos

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, GlobalFoundries, Nebius, Applied Digital, Intuit, Spotify, and More -- Barrons.com

21 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Ganhos

Stellantis Targets Distant but Constructive -- Market Talk

21 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

Comparação entre Pares

Variação de preço

CytoSorbents Corp Previsão

Preço-alvo

By TipRanks

63.04% parte superior

Previsão para 12 meses

Média 0.75 USD 63.04%

Máximo 0.75 USD

Mínimo 0.75 USD

Com base em 1 analistas de Wall Street que oferecem metas de preço de 12 meses para CytoSorbents Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

1 ratings

Comprar

Manter

Vender

Com base em 1 analistas que deram avaliações de ações para CytoSorbents Corp - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

0.705 / 0.771Suporte e Resistência

All events are bearish.

Sentimento

By Acuity

135 / 345 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre CytoSorbents Corp

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.